Neurol. praxi. 2018;19(5):365-368 | DOI: 10.36290/neu.2018.119

Hepatic impairment during the treatment multiple sclerosis by dimethyl-fumarate

MUDr. Květoslava Aiglová, Ph.D., prof. MUDr. Jiří Ehrmann, CSc.
II. interní klinika gastroenterologická a hepatologická, FN Olomouc

Dimethyl-fumarate (DMF) is a drug indicated for relapsing-remitting forms of multiple sclerosis. Treatment leads to reduction ofrelapses, delays invalidity and supresses manifestations of disease shown on MRI. Treatment by DMF has also side effects, includinggastrointestinal side effects and increase of liver enzymes activity. Clinical trials DEFINE and CONFIRM shown elevation of ALTin 6 % cases and discontinuation of treatment leaded do normalisation of liver tests. DMF is an effective and safe drug, possibleincreasing of liver tests does not mean serious risk, for which the treatment should by discontinued.

Keywords: multiple sclerosis, relapsing-remitting MS, dimethyl-fumarate, liver tests

Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Aiglová K, Ehrmann J. Hepatic impairment during the treatment multiple sclerosis by dimethyl-fumarate. Neurol. praxi. 2018;19(5):365-368. doi: 10.36290/neu.2018.119.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cohen JA, Barkhof F, Comi G. TRANSFORMS study. N Engl J Med 2010; 362: 402-415. Go to original source...
    2. Červinková Z, Šperl J. Toxické poškození jater. In Ehrmann J, Hůlek P. Hepatologie 2. vydání 2014; Grada Praha; 393-400.
    3. Devarbhavi H. An update on drug-induced liver injury. J Clin Exp Hepatol 2012; 2: 247-259. Go to original source...
    4. Ehrmann J, Procházka V, Schneiderka P. Diferenciální diagnostika ikteru. Postgrad Med 2001; 3. 912-926.
    5. Havrdová E. Dimethyl-fumarát. Remedia. 23. 4. 2014.
    6. Hui CK, Cheung WW, Leung KW, Cheng VC, Tang BS, Li IW, Luk JM, Lee NP. Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. Hepatology 2008; 48: 1-10. Go to original source...
    7. Jungst Ch, Yoo-Jin Kim, Lammert F. Severe drug-induced liver injury related to therapy with dimethyl-fumarate. 2016; http://doi.org/10.1002/hep.28652. Go to original source...
    8. Kieslichová E. Terapeutický přístup k akutnímu selhání jater. Habilitační práce 2018; UK Praha, 1. LF.
    9. Meluzínová E, Bortlík M. Dimethyl-fumarát v léčbě relaxující-remitující formy roztroušené sklerózy. KlinFarmakol Farm 2015; 29(3): 119-122.
    10. Piťha J, Vojtíšková J, Král N. Roztroušená skleróza. Doporučené diagnostické a terapeutické postupy pro všeobecné a praktické lékaře. Centrum doporučených postupů pro praktické lékaře; suplementum 2017.
    11. Prosperini L, Pontecorvo S. Dimethyl - in the management of multiple sclerosis: appropriate patient selection and special considetations. Therapeut Clin Risk Man 2016; 12: 339-350. Go to original source...
    12. Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Efficasy and safety of fumaric acid esters in the long-term treatment of psoriasis - a retrospective study. J Dtsch Dermatol Ges 2009; 7: 603-611. Go to original source... Go to PubMed...
    13. Sinagra E, Raimondo D, Cottone S, Guddo F, Gabriele Rizzo A, Amvrosiadis G, Perricone G, Cottone M, Madonia S. Does glatiramer acetate provoke hepatitis in multiple sclerosis? Mult Scler Relat Disord 2014; 3: 266-268. Go to original source... Go to PubMed...
    14. Szántová M, Sedlačko J, Jakobovičová M. Lieková a herbálna hepatotoxicita: přehlad klinických klasifikacií. Vnitřní Lék 2018; 64: 384-393. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.